{"id":9123,"name":"Vesalius Biocapital (Vesalius Ventures)","slug":"vesalius-biocapital-vesalius-ventures","website":"https://www.vesaliusbiocapital.com","hqGeo":"Ghent, Belgium","stageFocus":["Seed","Series A"],"sectorTags":["Other","Healthcare","EdTech"],"excludedSectors":[],"checkSizeMin":500000,"checkSizeMax":3000000,"thesisSummary":"Benelux-based healthcare investor backing biotech, medtech and digital health companies with strong science and clinical validation.","thesisNarrative":null,"logoUrl":null,"aumUsd":null,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"Confo Therapeutics","companyUrl":null,"stage":null,"sector":"Life Sciences","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Aphea.Bio","companyUrl":null,"stage":null,"sector":"Life Sciences","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"activaero","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Developed controlled breathing technologies and inhalation devices for therapeutics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Amakem","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Developed kinase inhibitors for eye diseases using Localized Drug Action platform.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"apitope","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"bienca","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Develops enzymatic systems for food protection using bio-mimicry technology.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"complix","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Develops novel protein therapeutics based on proprietary Alphabody technology.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Exact Imaging","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"FF Pharmaceuticals","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Fovea","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"GenKyoTex","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Developed therapeutics blocking oxygen radical production (IPO on Euronext).","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Genomic Vision","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"humedics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ncardia","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ogeda","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"omeicos therapeutics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Develops small molecule drugs from omega-3 metabolites for atrial fibrillation.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ProFibrix","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Promethera","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"skyline diagnostics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"softhale","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"trinean","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"trodmedical","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Develops Encage TM radiofrequency ablation device for prostate cancer.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"voluntis","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Develops digital therapeutics for diabetes, anticoagulation, and hemophilia (e.g., Insulin Therapy Manager).","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ENYO Pharma","companyUrl":null,"stage":"Series C-II","sector":"Biotechnology (therapeutics)","investmentYear":null,"description":"Develops Vonafexor for kidney diseases like Alport syndrome (Phase 2 data).","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"HepaRegeniX","companyUrl":null,"stage":"Not specified","sector":"Biotechnology (therapeutics, liver)","investmentYear":null,"description":"Develops HRX-215 to enhance liver regeneration (Phase Ib complete).","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Mecuris GmbH","companyUrl":null,"stage":"Growth/seed follow-on","sector":"Medical devices","investmentYear":null,"description":"Develops medical devices (growth funding via Vesalius III).","amountUsd":null,"relevanceNote":null,"fundName":"Vesalius III"},{"companyName":"Ncardia (formerly Pluriomics)","companyUrl":null,"stage":"Not specified","sector":"Biotechnology (drug discovery tools)","investmentYear":null,"description":"Develops human stem cell-based assay systems like Pluricyte Cardiomyocytes for drug discovery.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Nutrium","companyUrl":null,"stage":"Series A ($12M)","sector":"HealthTech/eHealth","investmentYear":null,"description":"Digital nutrition platform (Series A led by Vesalius).","amountUsd":null,"relevanceNote":null,"fundName":"Vesalius"},{"companyName":"Promethera Biosciences","companyUrl":null,"stage":"Not specified","sector":"Biotechnology (cell therapy)","investmentYear":null,"description":"Develops stem cell therapies for incurable liver diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Ogeda (formerly Euroscreen)","companyUrl":null,"stage":"Exit","sector":"Biotechnology (therapeutics)","investmentYear":null,"description":"Developed GPCR-targeted drugs for women's health, inflammation, and neurodegeneration.","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":6,"partners":[{"id":21354,"name":"Marc Lohrmann","title":"President And General Manager","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":21355,"name":"Wim Moens","title":"Managing Partner","seniority":null,"focusTags":["MedTech","Digital Health"],"linkedinUrl":"https://www.linkedin.com/in/wim-moens-0b1b2b","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":21364,"name":"Guy Geldhof","title":"CFO Vesalius Biocapital Fund 1, Partner Fund 2 and Managing Partner Fund 3","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":21369,"name":"Dr. Christian Schneider","title":"Managing Partner Vesalius Biocapital Fund 1, Fund 2 and Fund 3","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":21379,"name":"Stéphane Verdood","title":"Managing Partner Vesalius Biocapital Fund 1, Fund 2 and Fund 3","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":21390,"name":"Dr. David Braga Malta","title":"Venture Partner Vesalius Biocapital Fund 3","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsLast12Months":0},"investorType":"vc","preferredApproach":"warm intro preferred","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":6492,"name":"Breed Reply","slug":"breed-reply","logoUrl":null,"website":"https://www.reply.com/","stageFocus":[],"sectorTags":["Healthcare","Security"],"hqGeo":null},{"id":6827,"name":"Force Over Mass","slug":"force-over-mass","logoUrl":null,"website":"https://www.fomcap.com/","stageFocus":[],"sectorTags":["AI / ML","Developer Tools","Other","Fintech","SaaS","Healthcare","EdTech"],"hqGeo":null},{"id":1548,"name":"Health Innovation Capital","slug":"health-innovation-capital","logoUrl":null,"website":"https://www.healthinnovation.vc/","stageFocus":["Seed","Pre-Seed"],"sectorTags":["Healthcare"],"hqGeo":"Boston, MA"},{"id":12096,"name":"TeleHealth Ventures","slug":"telehealth-ventures","logoUrl":null,"website":"https://telehealthventures.com","stageFocus":["Seed"],"sectorTags":["Other","Healthcare"],"hqGeo":"Austin, TX"},{"id":1369,"name":"Sonder Health Ventures","slug":"sonder-health-ventures","logoUrl":null,"website":"https://sondercapital.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Healthcare","Other"],"hqGeo":"Austin, TX, USA"},{"id":11533,"name":"Nova Health Fund","slug":"nova-health-fund","logoUrl":null,"website":"https://www.independenthealth.com/","stageFocus":["Seed","Series A"],"sectorTags":["Healthcare","Other"],"hqGeo":"Minneapolis, MN"}],"featuredIn":[{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"series-a","displayName":"Series A Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"what-vcs-actually-look-for-pitch-deck","title":"What VCs Actually Look for in a Pitch Deck"},{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"},{"slug":"Finding-Investors-For-Startup-In-2026","title":"How to Find Investors for Your Startup in 2026 (Without Cold-Searching Databases)"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-04-12T09:35:31.637Z"}